Back to search
FDAFDA · Food and drugs·Recall number D-0711-2017

ATROPINE SULFATE 0.01% OPHTH, Ophthalmic, 0.01%, Rx only, 15 mL Glass /Multiple Dose vial, Prepared by Key Compounding Pharmacy

Published May 24, 2017 · Recall initiated: April 18, 2017

Summary

FDA records drug Class II recall D-0711-2017, published May 24, 2017 and initiated April 18, 2017. Recalling firm: Key Pharmacy and Compounding Center; Status: Terminated; Reported quantity: 60 mL total; Lot: Lot # 01-20-2017@17, Exp 4/20/2017; 01-23-2017@48, Exp 4/23/2017; 01-27-2017@17, Exp 4/27/2017; 01-31-2017@42, Exp 5/1/2017; 02-01-2017@35, Exp 5/2/2017; t02-07-2017@67, Exp 5/9/2017. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: The firm is recalling sterile compounded drugs within expiry due to lack of assurance of sterility.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Key Pharmacy and Compounding Center
Distributor
Distributed nationwide in U.S.A., Australia and Canada.
Lot
Lot # 01-20-2017@17, Exp 4/20/2017; 01-23-2017@48, Exp 4/23/2017; 01-27-2017@17, Exp 4/27/2017; 01-31-2017@42, Exp 5/1/2017; 02-01-2017@35, Exp 5/2/2017; t02-07-2017@67, Exp 5/9/2017.
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was ATROPINE SULFATE 0.01% OPHTH, Ophthalmic, 0.01%, Rx only, 15 mL Glass /Multiple Dose vial, Prepared by Key Compounding Pharmacy recalled?

Yes. FDA published recall D-0711-2017 on May 24, 2017. Reported hazard: Lack of Assurance of Sterility: The firm is recalling sterile compounded drugs within expiry due to lack of assurance of sterility.

What should I do if I have this product?

Voluntary: Firm initiated · Letter